REFERECES
- Afkarian, M., Sachs, M.C., Kestenbaum, B., Hirsch, I. B., Tuttle,
K.R., Himmelfarb, J. … de Boer, I.H. (2013). Kidney disease and
increased mortality risk in type 2 diabetes. Journal of American
Society of Nephrology , 24, 302-308. doi:10.1681/ASN.2012070718
- Batlle, D., Wysocki, J., Soler, M.J. (2012). Angiotensin-converting
enzyme 2: enhancing the degradation of angiotensin II as a potential
therapy for diabetic nephropathy. Kidney International ., 81,
520-528. doi:10.1038/ki.2011.381
- Bellucci, P.N., González Bagnes, M.F., Di Girolamo, G., González, C.D.
(2017). Potential Effects of Nonsteroidal Anti-Inflammatory Drugs in
the Prevention and Treatment of Type 2 Diabetes
Mellitus. Journal of Pharmacy Practice ., 30, 549-556. doi:
10.1177/0897190016649551
- Bilan, V.P., Salah, E.M., Bastacky, S., Jones, H.B., Mayers,
R.M., Zinker, B., Poucher, S.M., Tofovic, S.P. (2011). Diabetic
nephropathy and long-term treatment effects of rosiglitazone and
enalapril in obese ZSF1 rats. Journal of Endocrinology , 210,
293-308. doi: 10.1530/JOE-11-0122
- Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R.,
Davis, B., … Schnitzer, T.J. (2000). Comparison of upper
gastrointestinal toxicity of rofecoxib and naproxen in patients with
rheumatoid arthritis, VIGOR Study Group. New England Journal of
Medicine, 343, 1520–1528. doi: 10.1056/NEJM200011233432103
- Cases, A., Coll, E. (2005). Dyslipidemia and the progression of renal
disease in chronic renal failure patients. Kidney International, 99,
S87-S93. doi: 10.1111/j.1523-1755.2005.09916.x
- Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D.,
Rosano, G.M.,…Hutton, B. (2016). Cardiovascular and Renal
Outcomes of Renin-Angiotensin System Blockade in Adult Patients with
Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.PLoS Medicine , 13(3), e1001971.
doi:10.1371/journal.pmed.1001971
- Chalikias, G., Tziakas, D. (2020). Angiotensin Receptor Neprilysin
Inhibitors-2019 Update. Cardiovascular Drugs Ther apy,
10.1007/s10557-020-07015-8. doi:10.1007/s10557-020-07015-8
- Cheng, H., Wang, S., Jo, Y-I., Hao, C-M., Zhang, M., Fan, X.,
…Harris, R.C. (2007). Overexpression of cyclooxygenase-2
predisposes to podocyte injury. Journal of American Society of
Nephrol ., 18, 551-559. doi: 10.1681/ASN.2006090990
- Cheng, H.F., Harris, R.C. (2004). Cyclooxygenases, the kidney, and
hypertension. Hypertension, 43, 525-530. doi:
10.1161/01.HYP.0000116221.27079.ea
- Cho, J., Cooke, C.E., Proveaux, W. (2003). A retrospective review of
the effect of COX-2 inhibitors on blood pressure
change. American Journal of Therapy, 10, 311-317.
doi:10.1097/00045391-200309000-00002
- Delanaye P, Scheen AJ. Preventing and treating kidney disease in
patients with type 2 diabetes. Expert Opin Pharmacother .
2019;20(3):277-294. doi:10.1080/14656566.2018.1551362
- Dey, A., Maric, C., Kaesemeyer, W.H., Zaharis, C.Z., Stewart, J.,
Pollock, J.S., Imig, J.D. (2004). Rofecoxib decreases renal injury in
obese Zucker rats. Clinical Sciences (Lond) , 107, 561–570.
doi: 10.1042/CS20040125.
- EnayetAllah, A.E., Luria, A., Luo, B., Tsai, H-J., Sura, P., Hammock,
B.D., Grant, D.F. (2008). Opposite Regulation of Cholesterol Levels by
the Phosphatase and Hydrolase Domains of Soluble Epoxide Hydrolase.Journal of Biological Chemistry , 283, 36592-36598. doi:
10.1074/jbc.M806315200
- Ferro, C.L., Mark, P.B., Kanbay, M., Sarafidis, P., Heine,
G.H., Rossignol, P.,… Zoccali, C. (2018). Lipid management in
patients with chronic kidney disease Nature Review of
Nephrology , 14, 727-749. doi: 10.1038/s41581-018-0072-9
- Fujihara, C.K., Antunes, G.R., Mattar, A.L., Andreoli, N., Malheiros
D.M.A.C., … Zatz, R. (2003). Cyclooxygenase-2 (COX-2)
inhibition limits abnormal COX-2 expression and progressive injury in
the remnant kidney. Kidney International , 64, 2172-2181. doi:
10.1046/j.1523-1755.2003.00319.x
- Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S.,
…Slavich, G.M. (2019). Chronic inflammation in the etiology of
disease across the life span. Nature Medicine , 25, 1822-1832.
doi: 10.1038/s41591-019-0675-0
- Gartung, A., Yang, J., Sukhatme, V.P.,Bielenberg,
D.R.,…Panigrahy, D. (2019). Suppression of chemotherapy-induced
cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH
inhibitor. Proceedings of National Academy of Sciences USA ,
116, 1698-1703. doi:10.1073/pnas.1803999116
- Gassler, N., Elger, M., Kränzlin, B., Kriz, W., Gretz, N.,
…Hartmann, I. (2001). Podocyte injury underlies the progression
of focal segmental glomerulosclerosis in the fa/fa Zucker rat, Kidney
International, 60, 106-116. doi: 10.1046/j.1523-1755.2001.00777.x
- Grosser, T., Fries, S., FitzGerald, G.A. (2006). Biological basis for
the cardiovascular consequences of COX-2 inhibition: therapeutic
challenges and opportunities. Journal of Clinical
Investigation, 116, 4-15. doi:10.1172/JCI27291
- Grundy, S.M. (2006). Drug Therapy of the Metabolic Syndrome:
Minimizing the Emerging Crisis in Polypharmacy. Nature Review of Drug
Discovery, 5, 295-309. doi: 10.1038/nrd2005
- Harris, R.C. (2008). An update on cyclooxygenase-2 expression and
metabolites in the kidney. Current Opinion of Nephrology and
Hypertension , 17, 64-69. doi: 10.1097/MNH.0b013e3282f1bb7d
- Harris, T.R., Bettaieb, A., Kodani, S., Dong, H., Myers, R., …
Hammock, B.D. (2015) Inhibition of soluble epoxide hydrolase
attenuates hepatic fibrosis and endoplasmic reticulum stress induced
by carbon tetrachloride in mice. Toxicology and Applied Pharmacology,
286,102-111. doi: 10.1016/j.taap.2015.03.022
- Homer, B.L., Dower, K. (2018). 41-Week Study of Progressive Diabetic
Nephropathy in the ZSF1 fa/faCP Rat
Model. Toxicology and Pathology , 46, 976-977. doi:
10.1177/0192623318803278
- Horrillo, R., Planagumà, A., González-Périz, A., Ferré,
N.,…Clària, J. (2007). Comparative protection against liver
inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor
and a nonredox-type 5-lipoxygenase inhibitor. Journal of
Pharmacology and Experimental Therapeutics, 323, 778-786.
doi:10.1124/jpet.107.128264
- Hotamisligil, G.S. (2006). Inflammation and metabolic disorders.Nature , 444, 860–867. doi: 10.1038/nature05485
- Hye Khan, M.A,. Hwang, S.H., Sharma, A., Corbett, J.A., …Imig,
J.D. (2016). A dual COX-2/sEH inhibitor improves the metabolic profile
and reduces kidney injury in Zucker diabetic fatty
rat. Prostaglandins and Other Lipid Mediators , 125, 40-47. doi:
10.1016/j.prostaglandins.2016.07.003
- Hye Khan, M.A., Kolb, L., Skibba, M., Hartmann, M.,
Blöcher,
R.,… Imig, J.D. (2018). A novel dual PPAR-γ agonist/sEH
inhibitor treats diabetic complications in a rat model of type 2
diabetes. Diabetologia , 61, 2235-2246. doi:
10.1007/s00125-018-4685-0
- Hye Khan, M.A., Schmidt, J., Stavniichuk, A., Imig, J.D., Merk, D.
(2019). A dual farnesoid X receptor/soluble epoxide hydrolase
modulator treats non-alcoholic steatohepatitis in
mice. Biochemical Pharmacology , 166, 212-221. doi:
10.1016/j.bcp.2019.05.023
- Ilatovskaya, D.V., Palygin, O., Levchenko, V., Endres, B.T.,
Staruschenko, A. (2017). The Role of Angiotensin II in Glomerular
Volume Dynamics and Podocyte Calcium Handling. Scientific
Reports , 7, 299. doi: 10.1038/s41598-017-00406-2
- Imig, J.D. Walsh, K.A., Hye Khan, M.A., Nagasawa,
T., Cherian-Shaw, M., … Hammock, B.D. (2012) Soluble epoxide
hydrolase inhibition and peroxisome proliferator activated receptor γ
agonist improve vascular function and decrease renal injury in
hypertensive obese rats. Experimental Biology and Medicine
(Maywood) , 237, 1402-1412. doi: 10.1258/ebm.2012.012225
- Imig, J.D. (2018). Prospective for cytochrome P450 epoxygenase
cardiovascular and renal therapeutics. Pharmacology and
Therapeutics, 192, 1-19. doi: 10.1016/j.pharmthera.2018.06.015
- Imig, J.D., Zhao, X., Capdevila, J.H., Morisseau, C., Hammock, B.D.
(2002). Soluble epoxide hydrolase inhibition lowers arterial blood
pressure in angiotensin II hypertension. Hypertension . 39(2002)
690-694. doi: 10.1161/hy0202.103788
- Imig, J.D., Zhao, X., Zaharis, C.Z., Olearczyk, J.J., Pollock, D.M.,
… Hammock, B.D. (2005). An orally active epoxide hydrolase
inhibitor lowers blood pressure and provides renal protection in
salt-sensitive hypertension. Hypertension, 46, 975-981
- Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K.,…
Groop, L. (2001). Cardiovascular morbidity and mortality associated
with the metabolic syndrome. Diabetes Care , 24, 683-689. doi:
10.2337/diacare.24.4.683
- Kim, J., Yoon, S.P., Toews, ML, Imig, J.D., Hwang, S.H.,
…Padanilam, B. (2015). Pharmacological inhibition of soluble
epoxide hydrolase prevents renal interstitial fibrogenesis in
obstructive nephropathy. American Journal of Physiology Renal
Physiology, 308, F131-F139. doi: 10.1152/ajprenal.00531.2014
- Liu, Y., Dang, H., Li, D., Pang, W., Hammock, B.D., Zhu, Y. (2012).
Inhibition of Soluble Epoxide Hydrolase Attenuates
High-Fat-Diet–Induced Hepatic Steatosis by Reduced Systemic
Inflammatory Status in Mice. PLoS ONE , 7, e39165. doi:
10.1371/journal.pone.0039165
- Lorthioir, A., Guerrot, D., Joannides, R., Bellien, J. (2012).
Diabetic CVD–soluble epoxide hydrolase as a
target. Cardiovascular & Hematological Agents in Medicinal
Chemistry, 10, 212-222. doi: 10.2174/187152512802651042
- Ma, S., Zhu, X-Y., Eirin, A., Woollard, J.R. Jordan,
K.L.,…Lerman, L.O. (2016) Perirenal fat promotes renal arterial
endothelial dysfunction in obese swine 508 through tumor necrosis
factor-alpha. Journal of Urolpgy, 195, 1152–1259. doi:
10.1016/j.juro.2015.08.105
- Manhiani, M., Quigley, J.E., Knight, S.F., Tasoobshirazi, S.T., Moore,
T., … Imig, J.D. (2009). Soluble epoxide hydrolase gene
deletion attenuates renal injury and inflammation with DOCA-salt
hypertension. American Journal of Physiology Renal Physiology,297, F740-F748. doi: 10.1152/ajprenal.00098.2009
- Nandakishore R., Yalavarthi, P.R., Kiran, Y.R., Rajapranathi, M.
(2014). Selective cyclooxygenase inhibitors: current status.Current Drug Discovery and Technology , 11, 127-132.
doi:10.2174/1570163811666140127123717
- Nasrallah, R., Hassouneh, R., Hébert, R.L. (2016). PGE2, Kidney
Disease, and Cardiovascular Risk: Beyond Hypertension and
Diabetes. Journal of American Society of Nephrology, 27,
666-676. doi: 10.1681/ASN.2015050528
- Neckář. J., Kopkan. L., Husková, Z., Kolář, F., Papoušek, F.,…
Červenka, L. (2012). Inhibition of soluble epoxide hydrolase by
cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid
exhibits antihypertensive and cardioprotective actions in transgenic
rats with angiotensin II-dependent hypertension. Clinical
Science (London), 122, 513-525. doi: 10.1042/CS20110622
- Patti, A.M., Rizvi, A.A., Giglio, R.V., Stoian, A.P., Ligi, D.,
Mannello, F. (2020). Impact of Glucose-Lowering Medications on
Cardiovascular and Metabolic Risk in Type 2 Diabetes. Journal of
Clinical Medicine, 9, 912. doi:10.3390/jcm9040912
- PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver
disease via inhibiting NLRP3 inflammasome activation in
mice. Biochemical and Biophysical Research Communications , 523,
1020-1026. doi: 10.1016/j.bbrc.2019.12.131
- Ritz, E., Tarng, D.C. (2001). Renal disease in type 2
diabetes. Nephrology Dialysis and Transplantation, 5, 11-18.
doi: 10.1093/ndt/16.suppl_5.11
- Roche, C., Guerrot, D., Harouki, N., Duflot, T., Besnier,
M.,…Bellien, J. (2015). Impact of soluble epoxide hydrolase
inhibition on early kidney damage in hyperglycemic overweight mice.
Prostaglandins and Other Lipid Mediators, 120, 148-154. doi:
10.1016/j.prostaglandins.2015.04.011
- Rosenthal, T., Erlich, Y., Rosenmann, E., Grossman, E., Cohen, A.
(1995). Enalapril improves glucose tolerance in two rat models: a new
hypertensive diabetic strain and a fructose-induced hyperinsulinaemic
rat. Clinical and Experimental Pharmacology and Physiology,1995;22(1):S353-S354. doi: 10.1111/j.1440-1681.1995.tb02951.x
- Safaeian, L., Hajhashemi, V., Ajoodanian, M. (2018) The effect of
celecoxib on blood pressure and plasma oxidant/antioxidant status in
co-administration with glucocorticoid in rat. Biomed
Pharmacother , 108, 1804-1808. doi:10.1016/j.biopha.2018.10.047
- Saran, R., Robinson, B., Abbott, K.C., Bragg-Gresham, J., Xiaoying
Chen, X.,… Shahinian, V. (2020). US Renal Data System 2019
Annual Data Report: Epidemiology of Kidney Disease in the United
States. American Journal of Kidney Disease, 75, A6-A7. doi:
10.1053/j.ajkd.2019.09.003
- Su, Z., Widomski, D., Nikkel, A., Leys, L…,. McGaraughty, S.
(2018). Losartan improves renal function and pathology in obese ZSF-1
rats. Journal of Basic and Clinical Physiologyl Pharmacoogy,9(3), 281-290. doi:10.1515/jbcpp-2017-0157
- Toth-Manikowski, S., Atta, M.G. (2015). Diabetic Kidney Disease:
Pathophysiology and Therapeutic Targets. Journal of Diabetes
Research, . 2015, 697010. doi: 10.1155/2015/697010
- Vuorinen-Markkola, H., Yki-Järvinen, H. (1995). Antihypertensive
therapy with enalapril improves glucose storage and insulin
sensitivity in hypertensive patients with non-insulin-dependent
diabetes mellitus. Metabolism , 44, 85-89. doi:
10.1016/0026-0495(95)90293-7
- Warren, A.M., Knudsen, S.T., Cooper, M.E. (2019). Diabetic
nephropathy: an insight into molecular mechanisms and emerging
therapies. Expert Opinion in Therapeutic Targets , 23, 579-591.
doi: 10.1080/14728222.2019.1624721
- Williams, J.M., Sharma, M., Anjaiahh, S., Falck, J.R., Roman, R.J.
(2007). Role of endogenous CYP450 metabolites of arachidonic acid in
maintaining the glomerular protein permeability
barrier. American Journal of Physiology and Renal Physiology,293, F501-F505. doi: 10.1152/ajprenal.00131.2007
- Xie X, Atkins E, Lv J, Bennett, A.,…Rodgers, A. (2016). Effects
of intensive blood pressure lowering on cardiovascular and renal
outcomes: updated systematic review and meta-analysis. Lancet ,
387, 435-443. doi:10.1016/S0140-6736(15)00805-3
- Younossi, Z.M., Henry, L. (2019). The Impact of Obesity and Type 2
Diabetes on Chronic Liver Disease. American Journal of
Gastroenterology, 114, 1714-1715. doi: 10.14309/ajg.0000000000000433
- Zhang, X., Lerman, L.O. (2016). The metabolic syndrome and chronic
kidney disease. Translational Research, 183, 14-25. doi:
10.1016/j.trsl.2016.12.004
- Zhang, Y.F., Sun, C.C., Duan, J.X., Yang, H.H.,…Guan, C.X.
(2020). A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation
and puncture-induced sepsis in mice via anti-inflammation and
anti-oxidative stress. Biomeddical Pharmacotherapy , 126,
109907. doi:10.1016/j.biopha.2020.109907
- Zhao, X., Dey, A., Romanko, O.P., Stepp, D.W., Wang, H.H.,
…Imig, J.D. (2005). Decreased epoxygenase and increased epoxide
hydrolase expression in the mesenteric artery of obese Zucker rats.American Journal of Physiology Regulatory Integrative and
Comparative Physiology , 288, R188-R196. doi:
10.1152/ajpregu.00018.2004